最近的研究发现，编码 SWI/SNF 染色质重塑复合物 (SCRC) 亚基的基因异常表达和突变的发生率惊人地高。然而，SWI/SNF 基因异常表达和突变的致癌作用直到最近才被认识到，导致对这些修饰的了解相对有限。在本研究中，我们全面分析了SCRC相关基因（SCRGs）在泛癌中的表达差异、体细胞突变、潜在的生物学途径、基质或免疫细胞浸润以及药物敏感性。此外，还评估了肾透明细胞癌（KIRC）中 SCRG 的进化趋势、预后特征和免疫治疗反应。 SCRGs 的表达在 14 种肿瘤类型中的 13 种中发生变化，与预后密切相关，并且在 30.9% 的肿瘤患者中发生突变。 SCRGs还与免疫相关途径和肿瘤转移途径密切相关。 SCRGs的表达与免疫评分或基质评分呈正相关，但与肿瘤纯度呈负相关。确定了三种针对 SCRG 的潜在药物（FK866、Ispinesib mesylate 和 WZ3105）。在 KIRC 中，scRNA-seq 分析表明，在肿瘤细胞进展过程中，SCRC 的富集以及与免疫细胞的通讯频率显着下降。在 KIRC 中构建了预后特征，可有效预测 KIRC 的预后。分别通过 qRT-PCR 和 CCK-8 测定验证了从 KIRC 预后特征中鉴定出的 11 个预后基因的异常表达以及 FK866 和 Ispinesib mesylate 对 KIRC 的细胞毒性。我们的研究将 SCRG 确定为潜在的生物标志物和治疗靶点，为肿瘤靶向治疗的 SCRC 提供了新的见解。© 2024。作者。

Recent research has uncovered a surprisingly high occurrence of aberrant expression and mutations in the genes that encode subunits of the SWI/SNF chromatin-remodeling complexes (SCRC). Nevertheless, the carcinogenic effects of aberrant expression and mutations in SWI/SNF genes have only been acknowledged in recent times, resulting in a comparatively limited understanding of these modifications. In this study, we comprehensively analyzed the expression difference, somatic mutation, potential biological pathways, stromal or immune cell infiltration, and drug sensitivity of SCRC-related genes (SCRGs) in pan-cancer. Furthermore, the evolutionary trend, prognostic signature, and immunotherapy response of SCRGs in kidney renal clear cell carcinoma (KIRC) were also evaluated. The expression of SCRGs was changed in 13 out of 14 tumor types, strongly linked to prognosis, and mutated in 30.9% of tumor patients. SCRGs were also closely associated with immune-related pathways and tumor metastasis pathways. The expression of SCRGs was positively associated with the immune score or stromal score but negatively correlated with Tumor purity. Three potential drugs (FK866, Ispinesib mesylate, and WZ3105) were identified to target the SCRGs. In KIRC, scRNA-seq analysis showed that the enrichment of SCRC and the communication frequency with immune cells were significantly declined during tumor cell progression. A prognostic signature was constructed in KIRC and was effective in predicting the prognosis for KIRC. Aberrant expression of eleven prognostic genes identified from the KIRC prognostic signature and the cytotoxicity of FK866 and Ispinesib mesylate to KIRC were verified by qRT-PCR and CCK-8 assay, respectively. Our study identified SCRGs as potential biomarker and therapeutic targets, providing new insights into SCRC for tumor-targeted therapy.© 2024. The Author(s).